A startup developing a drug discovery platform capable of simultaneously measuring intracellular signals over time using proprietary technology, addressing multi-factor and multi-target drug discovery. Accelerating efficient and comprehensive new drug development through high-dimensional data and AI analysis.
A startup developing 3D game-based medical devices to comprehensively assess and treat executive function in children with ADHD. By combining game design with neuroscience, it advances digital transformation in healthcare and expands possibilities for supporting diverse children.
Remohab is a medical device startup from Osaka University, working on the development of a remote cardiac rehabilitation system. As the first company in the Japan Bio design Program, its participation in Air Water Group is the first M&A exit case in Japan in the DTx (Digital Therapeutics) field. In 2024, its completed Japan’s first physician-initiated Phase III clinical trial for a remote cardiac rehabilitation system, and on June 23, 2025, its product “Remohab CR U” received approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Remohab aims to launch the product in Japan first and promote its nationwide adoption with future global expansion in mind.
We provide real-time monitoring and predictive analytics for infrastructure assets such as bridges, roads, and towers. Powered by advanced evaluation technology originating from Kyoto University research, our solution enables timely maintenance to extend service life and reduce costs—helping create a safer, more sustainable society.
Leveraging world-leading autophagy measurement technology, we provide end-to-end solutions from material evaluation and supplement/cosmetic development to drug discovery research. A startup demonstrating results in international competitions, aiming for the societal implementation of extended healthy lifespans.